ACE and non-ACE mediated effect of angiotensin I on intracellular calcium mobilization in rat glomerular arterioles. Am J Physiol Heart Circ Physiol 284: H1933-H1941, 2003. First published February 13, 2003 10.1152/ajpheart.00042. 2003.-Because renin and angiotensin I (ANG I) level are high in the renal circulation, the conversion of ANG I is a critical step in the regulation of glomerular hemodynamics. We studied this conversion by investigating the effect of ANG I on intracellular Ca 2ϩ concentration ([Ca 2ϩ ]i) in rat juxtamedullary glomerular afferent and efferent arterioles (AA and EA, respectively). Two types of EA were considered, thin EA and muscular EA, terminating as peritubular capillaries and vasa rectae, respectively. In all arterioles, ANG I elicited [Ca 2ϩ ]i elevations. Maximal responses of 171 Ϯ 28 (AA), 183 Ϯ 7 (muscular EA), and 78 Ϯ 11 nM (thin EA) (n ϭ 6), similar to those obtained with ANG II, were observed with 100 nM ANG I. The EC50 values were 20 times higher for ANG I than for ANG II in AA (10.2 vs. 0.5) and muscular EA (6.8 vs. 0.4 nM) and 150 times higher in thin EA (15.2 vs. 0.1 nM). ANG I effect was blocked by losartan, indicating that AT1 receptors were involved. The ANG-converting enyzme (ACE) inhibitor lisinopril inhibited the maximal response to ANG I in AA and muscular EA by 75 Ϯ 9% (n ϭ 13) and 70 Ϯ 7% (n ϭ 13), respectively, but had no effect in thin EA (n ϭ 14). The serine protease inhibitor aprotinin, the chymase inhibitor chymostatin, and the cysteine protease inhibitors E64 and leupeptin had no effect on ANG I action. These data show that ANG I effects are mainly mediated by ACE in AA and muscular EA but not in thin EA. The lisinopril-insensitive response may be related to conversion by unknown enzyme(s) and/or to activation of AT1 receptors by ANG I.
IT IS NOW ACCEPTED that the renin-angiotensin system (RAS) acts as a local paracrine/autocrine system participating in the control of renal hemodynamic (9, 13, 30) . All components of RAS have been identified in the kidney (23) , and angiotensin II (ANG II) produced by cleavage of the phenylalanyl-histidyl peptide bond of angiotensin I (ANG I) is considered to be the major active peptide of the system. ANG-converting enzyme (ACE) is the major enzyme responsible for the generation of ANG II (10) . Because renin and ANG I levels are high in the renal circulation where renin is secreted by the afferent arterioles, the conversion of ANG I is a critical step in the regulation of the glomerular circulation. In the vessels, ACE is bound to membranes and localized on the endothelial cells surface and also, at least in the rat, in smooth muscle cells (7, 6) . ANG II may be formed intrarenally via ACE and other pathways, and its concentration has been reported to be 100 to 1,000 times higher in the kidney than in the plasma. Thus ANG II may be produced from plasma ANG I by action of ACE localized in the apical membranes of renal arteries, glomerular arterioles, and peritubular capillaries. ANG II may also be generated in the interstitial fluid by ACE present in this compartment or bound to the basolateral membrane of the proximal tubule (18) . Another possibility for the formation of ANG II is in the wall of intrarenal vessels from in situ synthesized ANG I. Indeed, the presence of renin has been observed in several types of renal arterioles (12, 30) . Studies of the regulation of renal RAS of diabetic rats have led Anderson et al. (3, 4) to suggest that the intrarenal RAS might be considered as two distinct systems: the tubulointerstitial RAS comprising primarily the proximal tubules and the interstitium and the vascular RAS comprising the renal vessels, the arterioles, and the glomeruli. It therefore appears that the renal glomerular arterioles are not only targets for ANG II action but may also be sites for synthesis of components of RAS. To further characterize the mechanisms involved in the formation of ANG II in the different types of glomerular arterioles, we investigated the effects of ANG I on the intracellular calcium concentration ([Ca 2ϩ ] i ) of juxtamedullary afferent (AA) and efferent (EA) arterioles and examined whether the responses were compatible with ANG II formation.
This was done by studying the action of the ANG II receptor antagonist losartan, of the ACE inhibitor lisinopril, and of some inhibitors of serine and cysteine proteases. Two types of EA, which are differently sensitive to ANG II (14) were studied, in parallel with AA: thin EA, which terminate as peritubular capillaries, and muscular EA, which terminate as vasa rectae. Our results show that ANG I increased [Ca 2ϩ ] i in the three types of glomerular arterioles through activation of the AT 1 receptors of ANG II. The effect of ANG I can be accounted for by ANG II formation catalyzed by ACE in AA and muscular EA but not in the thin EA.
MATERIALS AND METHODS
Microdissection of glomerular arterioles. Experiments were conducted on glomerular arterioles isolated from a rat kidney treated with collagenase as previously described (14) . The arterioles were microdissected from the juxtamedullary cortex at 4°C under a stereomicroscope (SZ3, Olympus; Tokyo, Japan). The arterioles were isolated with their attachment to the glomerulus and were then identified as AA and EA according to their morphology (14) by observation under a Nikon microscope (ϫ40 objective). AA are characterized by a thick and regular wall composed of uniformly distributed smooth muscle cells. Thin EA had a smaller diameter than AA and showed a bumpy wall due to the presence of irregularly shaped and nonclosely apposed smooth muscle cells. Muscular EA presented a thick, muscular, and regular wall similar to that of AA but had side branches that distinguish them from AA (14) . Before [Ca 2ϩ ]i measurements, each sample was transferred on a thin glass slide in 1 l of a standard solution containing 1% of agarose (type IX). Agarose was set by cooling the slide 1 min on ice. Arterioles were then loaded by the addition of 1 l of 10 M fura 2-AM and incubated for 1 h at room temperature in darkness.
Measurements of [Ca 2ϩ ]i. As in previous experiments (19), [Ca 2ϩ ]i was evaluated by using a Photoscan II microfluorimeter (Photon Technology International; Kontron, France). The glass slide with the sample was fixed at the bottom of a superfusion chamber, which was then put on the stage of an inverted fluorescent microscope (Nikon). The sample was continuously superfused with the standard solution (0.8 ml/ min, 37°C) that did or did not carry the test substances. The microscope was fitted with a quartz illumination system and a 40-fold magnification fluorescence objective. The sample was alternatively excited at 340 and 380 nm (4 s/cycle), and the fluorescence emitted at 510 nm from an area defined by an adjustable window (about 25 ϫ 30 m) was measured.
At the end of several experiments, autofluorescence was measured at 340 and 380 nm from the selected arteriolar area after the fura 2-AM fluorescence was quenched with 1 mM of a solution of MnCl 2 in the presence of 10 M ionomycin. The obtained values were very similar to the background emission from the same measurement window. Background was routinely recorded for both wavelengths at the end of each experiment and subtracted from all measurements. [Ca 2ϩ ]i was calculated from the following equation (11)
where Kd is the dissociation constant for the fura 2-Ca 2ϩ complex and is 224 nM, R is the ratio of fluorescence emitted for each wavelength (340/380 nm), R max is the maximal ratio emitted in the presence of saturating calcium (2 mM), Rmin is the minimal ratio measured in absence of calcium (0 mM), and ‫ץ‬ is the ratio of fluorescence obtained at 380 nm in absence and in presence of 2 mM calcium. The values of R min, Rmax, and ‫ץ‬ were periodically determined by external calibration using a buffer that mimicked intracellular medium (19 
where t0 is the time at the start of the [Ca 2ϩ ]i response and t1 is the time when the signal returns to baseline level.
Experimental protocols. The same protocols were applied to the three types of juxtamedullary arterioles. Dose-response relationships were obtained by successively superfusing the arterioles with increasing concentrations of ANG I (from 10 Ϫ10 to 10 Ϫ6 M) or ANG II (from 10 Ϫ12 to 10 Ϫ7 M). Each application lasted 5 min and was followed by a 15-min washing period, which was necessary to decrease [Ca 2ϩ ]i down to the basal level. The sensitivity of the ANG I effect to inhibitors was investigated in two ways. Either the tested inhibitor was added at the plateau phase of the response to ANG I (100 nM) or the arterioles received three successive 5-min applications of ANG I (100 nM), each followed by a 15-min washing period, and the inhibitor was added to the superfusate 10 min before and during the second application of ANG I. We verified that the inhibitors did not change the basal [Ca 2ϩ ]i level when superfused alone.
Solutions and products. The arterioles were superfused with a "standard solution" having the following composition (in mmol/l): 127 NaCl, 5 KCl, 0.8 MgSO 4, 0.33 Na2HPO4, 0.44 KH2PO4, 1 MgCl2, 4 NaHCO3, 2 CaCl2, 5 D-glucose, 10 CH3CO2Na, 20 HEPES, pH 7.4, and 0.1% BSA. Fura 2-AM was purchased from Molecular Probes (Leiden, The Netherlands); aprotinin was from Calbiochem (San Diego, CA); and DMSO, agarose, ANG I, ANG II, lisinopril, chymostatin, 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF), transepoxysuccinyl-L-leucylamido-(4-guanidino) butane (E64), and leupeptin were from Sigma (France).
Stock solutions of fura 2-AM (10 mM), chymostatin (20 mM), and E64 (20 mM) were prepared in DMSO. Stock solutions of all other drugs were prepared in distilled water. In the superfusion solutions, the concentrations of DMSO were equal or inferior to 0.5%. The superfusion solution containing 0.5% DMSO modified neither the basal [Ca 2ϩ ]i level nor the [Ca 2ϩ ]i response to ANG I. Statistics. Results are reported as means Ϯ SE. When each arteriole was its own control, significance was obtained by paired Student's t-test. Differences between two groups were analyzed using unpaired Student's t-test. Multiple comparisons in similar protocol were evaluated by ANOVA, followed by Bonferroni's test. The commercially available software (Prism 2.0, GraphPad Software; San Diego, CA) was used to fit dose-response curves and to estimate the EC 50 value (concentration of ANG I or ANG II giving half of maximal response). Values were considered significantly different at P Ͻ 0.05. [Ca 2ϩ ] i responses induced by ANG I in AA, muscular EA, and thin EA. In AA and both types of EA, superfusion of 100 nM ANG I elicited a rapid increase in [Ca 2ϩ ] i followed by a sustained plateau (Fig. 1) . The magnitude of the responses was similar in AA and muscular EA (145 Ϯ 12 nM, n ϭ 13 and 140 Ϯ 16 nM, n ϭ 12) but was significantly lower in thin EA (57 Ϯ 5 nM, n ϭ 17, P Ͻ 0.05). On ANG I removal, [Ca 2ϩ ] i slowly decreased to the basal level within about 10 min. The duration of the responses did not significantly differ among the three types of arterioles. It was of 13.9 Ϯ 0.9 min in AA (n ϭ 13), 13.5 Ϯ 1.0 min in muscular EA (n ϭ 12), and 16 Ϯ 1 min in thin EA (n ϭ 17). In all arterioles, a second application of ANG I elicited a response that had a magnitude similar to that of the first response, indicating the absence of homologous desensitization phenomenon. Table 1 . The arterioles were superfused with increasing concentrations of the peptide for 5 min at 15-min intervals. The concentrationresponse curves obtained with ANG I show that the maximal responses of all arterioles were reached with 100 nM. The magnitude of these responses were 171 Ϯ 28, 183 Ϯ 7, and 78 Ϯ 11 nM for AA, muscular, and thin EA, respectively. These values did not significantly differ from those obtained with a first application of 100 nM ANG I (see above). When compared with the maximal increases induced by ANG II, the maximal responses to ANG I were of greater magnitude in the muscular and thin EA, but the differences were not statistically significant. In the AA, the maximal responses were the same for both peptides. (Fig. 4) , indicating that the AT 1 receptors of ANG II are involved in the [Ca 2ϩ ] i responses to ANG I of the three types of arterioles.
RESULTS

Characterization of the
Effect of the ACE inhibitor lisinopril on the [Ca 2ϩ ] i responses to ANG I.
To determine whether the effects of ANG I is due to ANG II formed by ANG I hydrolysis by ACE, the effect of 10 M lisinopril was investigated. When lisinopril was applied before (10 min) and during the superfusion of 100 nM ANG I, it inhibited the [Ca 2ϩ ] i responses to ANG I of AA and muscular EA by 75 Ϯ 11% (n ϭ 6) and 65 Ϯ 8% (n ϭ 5), respectively, but it did not alter those of thin EA (n ϭ 7) (Fig. 5) . Inhibition was also observed when lisinopril was applied at the plateau of the [Ca 2ϩ ] i response to ANG I (Fig. 6) . Under these conditions, [Ca 2ϩ ] i increases were reversed by 74 Ϯ 7% and 75 Ϯ 6% in AA (n ϭ 7) and muscular EA (n ϭ 8), respectively, but the effect of lisinopril was very low and was not significant in thin EA (8 Ϯ 6%, n ϭ 6). In separate experiments, we 
Effect of serine and cysteine protease inhibitors on the [Ca 2ϩ
] i responses to ANG I. To investigate whether other proteases (5) are susceptible to hydrolyze ANG I into ANG II, we tested three inhibitors of serine proteases, the selective chymase inhibitor chymostatin, aprotinin, and the irreversible serine protease inhibitor AEBSF and two cysteine protease inhibitors E64 and leupeptin (24) . As indicated in Table 2 , only AEBSF produced a partial inhibition (36 Ϯ 6%) of the [Ca 2ϩ ] i increases induced by ANG I in the muscular EA.
DISCUSSION
There is much evidence that most intrarenal ANG II is locally formed to act as a paracrine/autocrine agent regulating renal hemodynamics (23) . Intrarenal ANG II can be generated from systemically delivered ANG I or from ANG I formed in the kidney by hydrolysis of plasma or renal angiotensinogen (21) . The amount of intrarenally synthesized ANG II is believed to depend essentially on the local level of ACE. This enzyme was found in the kidney vessels, tubules, and interstitium. In the present work, we were interested in the RAS of three types of juxtamedullary glomerular arterioles, namely AA, muscular EA, and thin EA. Except for the facts that these arterioles express the AT 1 and AT 2 ANG II receptors (22) and that AA and to a lesser extent EA possess a renin activity (12) that hydrolyzes angiotensinogen into ANG I, nothing was known about the fate of ANG I in these arterioles. Here we investigated the effect of ANG I in juxtaglomerular arterioles and tried to understand the mechanisms involved in the conversion of ANG I into active metabolites. The experimental approach consisted of superfusing isolated arterioles with the peptide and studying the effect of an AT 1 ANG II receptor antagonist, an ACE inhibitor, or serine and cysteine protease inhibitors. This should allow the establishment of whether the effect of ANG I is due to activation of AT 1 receptors and needs the conversion of ANG I into other active metabolites by ACE or other enzymes.
Our finding that ANG I was able to increase [Ca 2ϩ ] i in the three types of arterioles and that this increase was inhibited by losartan demonstrates that the observed effects resulted from activation of AT 1 ANG II receptors. With regard to the fact that the effect of superfused ANG I was sensitive to lisinopril in AA and muscular EA but not in the thin EA, it should be pointed that this was not related to differential accessibility of the endothelial cell layer where ACE is usually present. Indeed, we have previously reported that bradykinin, a direct endothelial activator, was able to produce [Ca 2ϩ ] i increases when it was superfused on the thin EA or AA and muscular EA (25) . Moreover, the [Ca 2ϩ ] i increases of thin EA and those of AA and muscular EA occurred after almost the same time delay (about 1 min) after the bradykinin superfusion was started. The responses developed even more rapidly in thin EA than in AA and muscular EA. We therefore interpret the lack of a lisinopril effect on the thin EA as an indication of the absence or the presence at a very low level of ACE activity in this type of arteriole. To date we do not know whether the effect of ANG I in thin EA is due to ANG I itself or to its conversion into ANG II and/or other active metabolites. It has indeed been reported that ANG I is able to bind to the AT 1 receptor expressed in Chinese hamster ovary cells lacking ACE and to activate the phospholipase C activity of these cells (27) with an EC 50 value ϳ200 times higher than that for ANG II. The observation of a similar difference (150 times) between the EC 50 values of ANG I and ANG II for increasing [Ca 2ϩ ] i in the thin EA supports the hypothesis that ANG I can directly activate the arteriolar AT 1 receptor without prior cleavage into ANG II or other active products, as suggested by Itskovitz and Odya (16) . Nevertheless, the conversion of ANG I into active metabolites is also a likely possibility. Alternative pathways to ACE for generating ANG II involving serine proteases such as chymase or a kallikrein-like protease sensitive to aprotinin have been described in the heart and kidney (1, 2, 17, 26, 29) . However, these two proteases probably do 
The tested inhibitor concentrations were of 100 M for chymostatin, AEBSF, E64, and leupeptin and of 100 U for aprotinin. In all arterioles, the chymase protease inhibitor chymostatin, the serine protease inhibitor aprotinin, and the cysteine protease inhibitor E64 and leupeptin had no effect on ANG I action. Only, the irreversible serine protease inhibitor AEBSF had a partial (ϳ30%) inhibitory effect in muscular EA. not participate in the generation of ANG II from ANG I in the thin EA, because the effect of ANG I was not altered by the chymase inhibitor chymostatin, by aprotinin, or by the irreversible serine protease inhibitor AEBSF. Also, the participation of cysteine proteases is unlikely because neither leupeptin nor E64 had an effect on the ANG I response. The same applies to ACE2, a carboxypeptidase recently found in the heart, testis, and kidney (8, 28) , because it produces ANG (1-9), which is then converted into ANG (1-7), which was found to be an inactive peptide in our system (see below).
Additional investigation is required to identify the putative enzyme(s) metabolizing ANG I in the thin EA. A study of the effect of ANG I metabolites on calcium mobilization in the arterioles might help to understand the pathways involved in the effect of ANG I. Among all peptides tested, only desp-Asp 1 -ANG II (ANG III) and des-Asp1-ANG I increased the [Ca 2ϩ ] i level in the thin EA and also in the AA and the muscular EA (15) . The responses obtained with maximal concentrations of these peptides were of a similar magnitude as those obtained with ANG II. Very small responses were observed with des-Asp 1 -Arg 2 -ANG II (ANG IV) and no response at all with des-Phe 8 -ANG II (ANG 1-7). Interestingly, des-Asp 1 -ANG I, which can be cleaved by ACE to produce ANG III, behaved like ANG I, in that its effects were inhibited by losartan in the three types of arterioles, not sensitive to lisinopril in thin EA, but sensitive to this ACE inhibitor in the AA and muscular EA (data not shown). This confirms that, contrary to AA and muscular EA, the thin EA lacks ACE. The presence of lisinopril-sensitive ACE activity in AA and muscular EA, but apparently not in the thin EA, could contribute to fact that the EC 50 value of ANG I for increasing [Ca 2ϩ ] i is largely different from that of ANG II (150 times higher) in the thin, whereas the difference is less marked in AA and muscular EA (about only 20 times). Thus the activation of ANG I into ANG II, if any, would be much less efficient in the thin EA.
The physiological implications of these observations remain unknown at the present time. Our study shows that ACE is present in AA but not in all EA. In the muscular EA, which divide into several branches to form vasa rectae and supply blood flow to renal medulla, ANG II synthetized locally by ACE can influence medulla microcirculation. On the contrary, the thin EA, which terminate in the inner cortex as peritubular capillaries, do not contain ACE, and ANG I activation is either nil or very slow in that vessel. This may be a mechanism protecting the glomerular and peritubular circulation against excess vasocontriction and protecting renal excretory functions. This remains however speculative. Moreover, ANG II can be produced by ACE present in plasma and interstitium and acts on thin EA.
In conclusion, the present work shows that AA and muscular EA, but not the thin EA, contain ACE activity able to generate ANG II from ANG I that is responsible for a large fraction (up to 70%) of the [Ca 2ϩ ] i increase induced by ANG I. The observation of ACEindependent effects of ANG I and des-Asp-ANG I requires further investigation to establish whether these peptides are converted into ANG II and III by arteriolar enzymes other than ACE. A search for such enzymes in the kidney of ACE knockout mice is a possible approach to this question.
